Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin or Crizotinib with Chemotherapy in ALCL
NCT01979536Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2013
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin, crizotinib in Anaplastic Large Cell Lymphoma ALK-positive, sponsored by National Cancer Institute. Started Nov 2013; status: completed.
02
Drugs
brentuximab vedotincrizotinib
03
Conditions
Anaplastic Large Cell Lymphoma ALK-positive
Beyond the preview
Go deeper on NCT01979536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01979536.